TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
UNC at Chapel Hill
We are doing this study because we want to find out if this approach will provide a longer period of disease response and is safe. The researchers conducting this study plan to publish the information they learn from this study in medical journals and at medical conferences.
Enrollment Form
This study is currently enrolling.